Meeting
2018 ASCO Annual Meeting
KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.
Authors
Yung-Jue Bang
Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of (South), Korea
Yung-Jue Bang , Eric Van Cutsem , Charles S. Fuchs , Atsushi Ohtsu , Josep Tabernero , David H. Ilson , Woo Jin Hyung , Vivian E. Strong , Thorsten Oliver Goetze , Takaki Yoshikawa , Laura H. Tang , Peggy May Tan Hwang , Kohei Shitara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03221426
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4136)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4136
Abstract #
TPS4136
Poster Bd #
322b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2021 ASCO Annual Meeting
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.
First Author: Yelena Y. Janjigian
Poster
2023 ASCO Annual Meeting
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.
First Author: Sun Young Rha
Poster
2021 Gastrointestinal Cancers Symposium
Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
First Author: Josep Tabernero